title: Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab.
authors.forename: Stefan J R
authors.initials: SJ
authors.lastname: de Geus
authors.forename: Martine J
authors.initials: MJ
authors.lastname: Jager
authors.forename: Gré P M
authors.initials: GP
authors.lastname: Luyten
authors.forename: Greet
authors.initials: G
authors.lastname: Dijkman
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D018450:Disease Progression; D005260:Female; D006801:Humans; D008266:Macula Lutea / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab